SpringWorks Therapeutics Stock (NASDAQ: SWTX)

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

Analog Devices, Philips And 3 Stocks To Watch Heading Into Wednesday

News

Short Ideas

Markets

Trading Ideas

LUNG

SWTX

Top 3 Health Care Stocks You May Want To Dump In February

Uber Weride

Equities

Mid Cap

Movers

AXSM

CRSP

MKGAF

MKKGY

NVDA

RXRX

TEVA

VNET

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

biotech shutter

Biotech

Health Care

General

SpringWorks&#39; Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.

SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Small Cap

Opinion

Press Releases

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

Biotech Investing: How PRVs Can Unlock Major Opportunities

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

Earnings

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

DAWN

IBRX

IOVA

ONCY

PTCT

SNDX

TSX:ONC

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Alvotech

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Nuvalent

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

Wedbush

Evercore ISI Group

Guggenheim

JP Morgan

Comments

SpringWorks Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga